Combination Therapy Strategy

1. Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial; 2. On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
1、对于接受系统治疗的晚期肝细胞癌患者，手术切除可能带来额外获益。然而，目前支持该手术的高质量证据尚属空白。TALENTOP研究旨在明确，对于经系统治疗后获得缓解的晚期肝细胞癌患者，手术切除能否带来生存获益。2、经动脉化疗栓塞（TACE）是中期肝细胞癌的标准治疗，但生存 …
DOI